Global adalimumab market is expected to undergo significant growth during the forecast period, 2024-2028. The rising prevalence of arthritis coupled with large number of clinical trials is impelling the growth of the market. Adalimumab is an anti-TNF drug which is used for the treatment of rheumatoid arthritis, psoriatic arthritis, psoriasis and ulcerative colitis. Adalimumab lowers the chances of inflammatory response by binding to a TNFα. Adalimumab are currently being marketed in over 60 countries around the world.

Several companies are undergoing extensive clinical trials and R&D activities, which in turn, is expected to augment a major growth factor for global adalimumab market. The reimbursement coverage and well-defined regulatory guidelines are further expected to fuel the market growth through 2028. However, patent expiration of blockbuster drugs is expected to slow down the market growth. Besides, side effects associated with the drugs is expected to restrain the growth of the market.

Global adalimumab market is segmented based on based on type, product type, therapeutic area, distribution channel, end user, company and region. Based on therapeutic area, the market is categorized into rheumatoid arthritis, psoriatic arthritis, psoriasis, Crohn’s disease, and others. Among them, the rheumatoid arthritis is expected to dominate the global market owing to high prevalence among elderly population.

Regionally, North America is expected to dominate the global adalimumab market followed by Europe. The advanced healthcare infrastructure and well-organized regulatory framework in these two regions is making them a lucrative market for adalimumab manufacturers.

Major companies operating in global adalimumab market include Abbvie Inc., Pfizer Inc., Amgen Inc., Novartis AG, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd, Boehringer Ingelheim International GmbH, Mylan N.V., Hetero Biopharma Ltd., and Samsung Bioepis Co Ltd. The market players are undergoing extensive clinical trials to test the safety and efficacy of the adalimumab in treatment of various diseases.

Objective of the Study:

  • To analyse and forecast the market size of global adalimumab market.
  • To forecast global adalimumab market based on based on type, product type, therapeutic area, distribution channel, end user, company and region.
  • To identify drivers and challenges for global adalimumab market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global adalimumab market.
  • To identify and analyse the profile of leading players operating in the global adalimumab market.


Download Free Sample Report

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of adalimumab manufacturing companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research.

TechSci Research calculated global adalimumab market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analysing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.

Key Target Audience:

  • Adalimumab manufacturers, companies, partners, hospitals pharmacy/retail pharmacy and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to adalimumab
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as adalimumab manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Attribute

Details

Base Year

2022

Historical Data

2018 – 2021

Estimated Year

2023

Forecast Period

2024 – 2028

Quantitative Units

Revenue in USD Million and CAGR for 2018-2022 and 2023E-2028F

 

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

 

Segments covered

·         Type

·         Product Type

·         Therapeutic Area

·         Distribution Channel

·         End User

·         Region

Regional scope

North America; Europe; Asia Pacific; South America; Middle East & Africa

Country scope

United States, Mexico, Canada, China, India, Japan, South Korea, Australia, Germany, France, United Kingdom, Spain, Italy, South Africa, UAE, Saudi Arabia, Brazil, Argentina, Colombia

Key companies profiled

Abbvie Inc., Pfizer Inc., Amgen Inc., Novartis AG, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd, Boehringer Ingelheim International GmbH,      Mylan N.V., Hetero Biopharma Ltd., and Samsung Bioepis Co Ltd.

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Report Scope:

In this report, global adalimumab market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Adalimumab Market, By Type:
    • Biologics
    • Biosimilar
  • Global Adalimumab Market, By Product Type:
    • Branded
    • Generics
  • Global Adalimumab Market, By Therapeutic Area:
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Psoriasis
    • Crohn’s Disease
    • Others
  • Global Adalimumab Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Others
  • Global Adalimumab Market, By End User:
    • Hospitals & Clinics
    • Home Healthcare
    • Others

·         Global Adalimumab Market, By Region:

    • Asia-Pacific
      • China
      • Japan
      • India 
      • South Korea
      • Australia
    • Europe
      • France
      • Germany
      • United Kingdom
      • Italy
      • Spain
    • North America
      • United States
      • Mexico
      • Canada
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global adalimumab market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

  • Profit margin analysis in case of direct and indirect sales channel.

It is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

4.1.  Adalimumab Demand, By Therapeutic Area

4.2.  Adalimumab Demand, By Region

4.3.  Adalimumab Demand, By Gender

4.4.  Adalimumab Demand, By Patient Population

4.5.  Commonly Observed Side-Effects

4.6.  Brand Awareness

5.    Pharmacodynamic Overview of Adalimumab

5.1.  Mechanism of Action

5.2.  Absorption

5.3.  Volume of Distribution

5.4.  Route of Elimination

5.5.  Half Life

5.6.  Clearance

5.7.  Toxicity

6.    Clinical Trials

6.1.  Ongoing Clinical Trials

6.2.  Completed Clinical Trials

6.3.  Terminated Clinical Trials

6.4.  Clinical Trial Analysis

7.    Patent Analysis

7.1.  Patent Granted

7.2.  Patent Applications Filed

8.    Global Adalimumab Market Outlook

8.1.  Market Size & Forecast

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Type (Biologics v/s Biosimilars)

8.2.2.     By Product Type (Branded v/s Generics)

8.2.3.     By Therapeutic Area (Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn’s Disease, Others)

8.2.4.     Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)

8.2.5.     By End User (Hospitals & Clinics, Home Healthcare, Others)

8.2.6.     By Company (2022)

8.2.7.     By Region

8.3.  Product Market Map

9.    North America Adalimumab Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value & Volume

9.2.  Market Share & Forecast

9.2.1.     By Type

9.2.2.     By Product Type

9.2.3.     By Therapeutic Area

9.2.4.     By Distribution Channel

9.2.5.     By End User

9.2.6.     By Country

9.3.  North America: Country Analysis

9.3.1.     United States Adalimumab Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Type

9.3.1.2.2.             By Product Type

9.3.1.2.3.             By Therapeutic Area

9.3.1.2.4.             By Distribution Channel

9.3.1.2.5.             By End User

9.3.2.     Mexico Adalimumab Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Type

9.3.2.2.2.             By Product Type

9.3.2.2.3.             By Therapeutic Area

9.3.2.2.4.             By Distribution Channel

9.3.2.2.5.             By End User

9.3.3.     Canada Adalimumab Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Type

9.3.3.2.2.             By Product Type

9.3.3.2.3.             By Therapeutic Area

9.3.3.2.4.             By Distribution Channel

9.3.3.2.5.             By End User

10.  Europe Adalimumab Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value & Volume

10.2.              Market Share & Forecast

10.2.1.  By Type

10.2.2.  By Product Type

10.2.3.  By Therapeutic Area

10.2.4.  By Distribution Channel

10.2.5.  By End User

10.2.6.  By Country

10.3.              Europe: Country Analysis

10.3.1.  France Adalimumab Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Type

10.3.1.2.2.           By Product Type

10.3.1.2.3.           By Therapeutic Area

10.3.1.2.4.           By Distribution Channel

10.3.1.2.5.           By End User

10.3.2.  Germany Adalimumab Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Type

10.3.2.2.2.           By Product Type

10.3.2.2.3.           By Therapeutic Area

10.3.2.2.4.           By Distribution Channel

10.3.2.2.5.           By End User

10.3.3.  United Kingdom Adalimumab Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Type

10.3.3.2.2.           By Product Type

10.3.3.2.3.           By Therapeutic Area

10.3.3.2.4.           By Distribution Channel

10.3.3.2.5.           By End User

10.3.4.  Italy Adalimumab Market Outlook

10.3.4.1.      Market Size & Forecast

10.3.4.1.1.           By Value

10.3.4.2.      Market Share & Forecast

10.3.4.2.1.           By Type

10.3.4.2.2.           By Product Type

10.3.4.2.3.           By Therapeutic Area

10.3.4.2.4.           By Distribution Channel

10.3.4.2.5.           By End User

10.3.5.  Spain Adalimumab Market Outlook

10.3.5.1.      Market Size & Forecast

10.3.5.1.1.           By Value

10.3.5.2.      Market Share & Forecast

10.3.5.2.1.           By Type

10.3.5.2.2.           By Product Type

10.3.5.2.3.           By Therapeutic Area

10.3.5.2.4.           By Distribution Channel

10.3.5.2.5.           By End User

11.  Asia-Pacific Adalimumab Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value & Volume

11.2.              Market Share & Forecast

11.2.1.  By Type

11.2.2.  By Product Type

11.2.3.  By Therapeutic Area

11.2.4.  By Distribution Channel

11.2.5.  By End User

11.2.6.  By Country

11.3.              Asia-Pacific: Country Analysis

11.3.1.  China Adalimumab Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Type

11.3.1.2.2.           By Product Type

11.3.1.2.3.           By Therapeutic Area

11.3.1.2.4.           By Distribution Channel

11.3.1.2.5.           By End User

11.3.2.  India Adalimumab Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Type

11.3.2.2.2.           By Product Type

11.3.2.2.3.           By Therapeutic Area

11.3.2.2.4.           By Distribution Channel

11.3.2.2.5.           By End User

11.3.3.  South Korea Adalimumab Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Transgenic Crop

11.3.3.2.2.           By Technique

11.3.3.2.3.           By Application

11.3.3.2.4.           By End User

11.3.4.  Japan Adalimumab Market Outlook

11.3.4.1.      Market Size & Forecast

11.3.4.1.1.           By Value

11.3.4.2.      Market Share & Forecast

11.3.4.2.1.           By Type

11.3.4.2.2.           By Product Type

11.3.4.2.3.           By Therapeutic Area

11.3.4.2.4.           By Distribution Channel

11.3.4.2.5.           By End User

11.3.5.  Australia Adalimumab Market Outlook

11.3.5.1.      Market Size & Forecast

11.3.5.1.1.           By Value

11.3.5.2.      Market Share & Forecast

11.3.5.2.1.           By Type

11.3.5.2.2.           By Product Type

11.3.5.2.3.           By Therapeutic Area

11.3.5.2.4.           By Distribution Channel

11.3.5.2.5.           By End User

12.  South America Adalimumab Market Outlook

12.1.              Market Size & Forecast

12.1.1.  By Value & Volume

12.2.              Market Share & Forecast

12.2.1.  By Type

12.2.2.  By Product Type

12.2.3.  By Therapeutic Area

12.2.4.  By Distribution Channel

12.2.5.  By End User

12.2.6.  By Country

12.3.              South America: Country Analysis

12.3.1.  Brazil Adalimumab Market Outlook

12.3.1.1.      Market Size & Forecast

12.3.1.1.1.           By Value

12.3.1.2.      Market Share & Forecast

12.3.1.2.1.           By Type

12.3.1.2.2.           By Product Type

12.3.1.2.3.           By Therapeutic Area

12.3.1.2.4.           By Distribution Channel

12.3.1.2.5.           By End User

12.3.2.  Argentina Adalimumab Market Outlook

12.3.2.1.      Market Size & Forecast

12.3.2.1.1.           By Value

12.3.2.2.      Market Share & Forecast

12.3.2.2.1.           By Type

12.3.2.2.2.           By Product Type

12.3.2.2.3.           By Therapeutic Area

12.3.2.2.4.           By Distribution Channel

12.3.2.2.5.           By End User

12.3.3.  Colombia Adalimumab Market Outlook

12.3.3.1.      Market Size & Forecast

12.3.3.1.1.           By Value

12.3.3.2.      Market Share & Forecast

12.3.3.2.1.           By Type

12.3.3.2.2.           By Product Type

12.3.3.2.3.           By Therapeutic Area

12.3.3.2.4.           By Distribution Channel

12.3.3.2.5.           By End User

13.  Middle East and Africa Adalimumab Market Outlook

13.1.              Market Size & Forecast

13.1.1.  By Value & Volume

13.2.              Market Share & Forecast

13.2.1.  By Type

13.2.2.  By Product Type

13.2.3.  By Therapeutic Area

13.2.4.  By Distribution Channel

13.2.5.  By End User

13.2.6.  By Country

13.3.              MEA: Country Analysis

13.3.1.  South Africa Adalimumab Market Outlook

13.3.1.1.      Market Size & Forecast

13.3.1.1.1.           By Value

13.3.1.2.      Market Share & Forecast

13.3.1.2.1.           By Type

13.3.1.2.2.           By Product Type

13.3.1.2.3.           By Therapeutic Area

13.3.1.2.4.           By Distribution Channel

13.3.1.2.5.           By End User

13.3.2.  Saudi Arabia Adalimumab Market Outlook

13.3.2.1.      Market Size & Forecast